AveXis (NASDAQ:AVXS) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued on Tuesday, January 9th.
According to Zacks, “AveXis, Inc. is a gene therapy company which develops and commercializes treatments for neurological genetic diseases primarily in United States. The Company’s product candidate consists of AVXS-101 which is in clinical trial for the treatment of spinal muscular atrophy Type 1, the genetic cause of infant mortality. AveXis, Inc. is headquartered in Bannockburn, Illinois. “
A number of other equities research analysts also recently weighed in on the company. Royal Bank of Canada reaffirmed a “hold” rating and set a $92.00 price objective on shares of AveXis in a report on Thursday, November 2nd. Citigroup set a $132.00 target price on AveXis and gave the stock a “buy” rating in a report on Friday, January 5th. Chardan Capital reissued a “buy” rating and issued a $135.00 target price on shares of AveXis in a report on Friday, January 5th. UBS Group set a $122.00 target price on AveXis and gave the stock a “buy” rating in a report on Friday, January 5th. Finally, BMO Capital Markets restated an “outperform” rating and issued a $123.00 price objective on shares of AveXis in a research report on Saturday, September 30th. Three research analysts have rated the stock with a sell rating, four have given a hold rating and fourteen have issued a buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $112.84.
AveXis (NASDAQ:AVXS) last issued its quarterly earnings results on Thursday, November 9th. The company reported ($1.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.48) by ($0.04). During the same quarter in the previous year, the company posted ($0.87) earnings per share. equities analysts expect that AveXis will post -6.23 EPS for the current year.
In related news, VP Sukumar Nagendran sold 1,780 shares of the firm’s stock in a transaction dated Wednesday, November 1st. The shares were sold at an average price of $101.26, for a total value of $180,242.80. Following the completion of the sale, the vice president now directly owns 1,780 shares in the company, valued at approximately $180,242.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Andrew F. Knudten sold 2,000 shares of the firm’s stock in a transaction dated Monday, December 4th. The shares were sold at an average price of $94.48, for a total transaction of $188,960.00. Following the completion of the sale, the vice president now owns 7,000 shares of the company’s stock, valued at $661,360. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 52,340 shares of company stock valued at $5,318,845. Company insiders own 18.60% of the company’s stock.
A number of institutional investors have recently added to or reduced their stakes in AVXS. Strs Ohio bought a new position in AveXis in the 3rd quarter valued at about $116,000. Ameritas Investment Partners Inc. raised its holdings in AveXis by 331.0% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,112 shares of the company’s stock valued at $174,000 after acquiring an additional 1,622 shares during the period. Cubist Systematic Strategies LLC raised its holdings in AveXis by 688.6% in the 3rd quarter. Cubist Systematic Strategies LLC now owns 1,806 shares of the company’s stock valued at $175,000 after acquiring an additional 1,577 shares during the period. Teacher Retirement System of Texas bought a new position in AveXis in the 3rd quarter valued at about $200,000. Finally, Deschutes Portfolio Strategy LLC bought a new position in AveXis in the 3rd quarter valued at about $203,000. 92.88% of the stock is currently owned by hedge funds and other institutional investors.
WARNING: “AveXis (AVXS) Lifted to Hold at Zacks Investment Research” was published by BBNS and is the property of of BBNS. If you are reading this report on another publication, it was illegally copied and republished in violation of United States and international copyright and trademark law. The legal version of this report can be viewed at https://baseballnewssource.com/markets/avexis-avxs-upgraded-by-zacks-investment-research-to-hold/1823886.html.
AveXis Company Profile
AveXis, Inc is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AveXis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis and related companies with our FREE daily email newsletter.